SLU Researcher Finds Help for Alzheimer's-Associated Agitation with New FDA-Approved Treatment
ST. LOUIS – A Saint Louis University researcher was instrumental in developing the first and only Food and Drug Administration (FDA) approved treatment for agitation associated with Alzheimer’s dementia.
In a paper published in JAMA Neurology, senior author and the inaugural Henry & Amelia Nasrallah Endowed Professor and Director of Geriatric Psychiatry at Saint Louis University George T. Grossberg, M.D., and colleagues shared the results of a national clinical trial. They discovered that REXULTI, also called brexpiprazole, significantly reduced agitation in patients with Alzheimer’s disease and was well tolerated with few side effects.
George Grossberg, M.D. Photo by Sarah Conroy.
Earlier this year, brexpiprazole became the first FDA-approved treatment of agitation-associated Alzheimer’s dementia.
Of the 6.7 million people 65 and older in the US with Alzheimer’s dementia, multiple studies show that about half or more develop agitation.
Agitation associated with Alzheimer’s dementia may include activities like restlessness or more aggressive behavior, like screaming, destroying objects or fighting. Frequent and severe behavioral symptoms can be extremely distressing to the person with Alzheimer’s disease, as well as their families and caregivers.
Antipsychotic drugs are commonly prescribed “off-label” to treat symptoms like aggression and agitation. While these antipsychotics seem to show a modest benefit in treating aggression in the short term, they have adverse effects and other health risks that limit their use over more extended periods.
“When patients with Alzheimer’s dementia develop agitation symptoms, they can become increasingly difficult to manage,” said Grossberg, who is also director of geriatric psychiatry at SLU. “I’m encouraged by the findings of this study which show that brexpiprazole is an effective and well-tolerated medication that can treat the often-debilitating symptoms of agitation associated with dementia due to Alzheimer’s disease.”
In the multicenter Phase 3 clinical trial, researchers evaluated the efficacy and safety of brexpiprazole, a medication used for the treatment of major depressive disorder and schizophrenia, for patients with agitation associated with Alzheimer’s.
The clinical trial was a 12-week, double-blind, placebo-controlled, fixed-dose, parallel-arm trial that enrolled 345 participants at 123 clinical trial sites in Europe and the United States.
Investigators enrolled participants between the ages of 55 to 90 with a diagnosis of probable Alzheimer’s disease and clinically significant symptoms of agitation who lived in a care facility or community-based setting.
Participants were randomly assigned to receive the study drug or a placebo. To participate in the clinical trial, participants had to be stable and have a caregiver who could comply with the study procedures.
“It can be extremely challenging to care for patients with Alzheimer’s disease,” said Grossberg. “Having new medications to help patients who are suffering will enormously benefit patients, healthcare providers, and those caring for their loved ones.”
The clinical trial was supported by Otsuka Pharmaceutical Development & Commercialization and H. Lundbeck.
For more information about the trial, visit ClinicalTrials.gov. The study’s Clinical Trials Identifier is NCT03548584.
Latest Newslink
- Saint Louis University Staff, Faculty Participate in Civil Rights Immersion TripSupported by the Office of Mission and Identity, Saint Louis University employees recently participated in a Civil Rights immersion trip. The group of nine, led by Patrick Cousins, pastoral formation director in Mission and Identity, took a road trip from SLU’s campus in St. Louis to sites in Tennessee, Alabama and Georgia after the spring semester ended.
- Saint Louis University Provides a Space for Religious Discernment to FlourishSaint Louis University provides an institutional framework to support men and women seeking religious vocations. Founded in 1889, SLU’s College of Philosophy and Letters oversees undergraduate and graduate programs oriented by the Jesuit commitment to intelligent service of faith and justice in dialogue with culture. The programs provide the philosophical and intellectual background needed for further studies in theology and ministry for future priests and nuns, as well as engaged laity within the Catholic Church.
- Helen De Cruz, Ph.D.: 1978-2025Helen De Cruz, Ph.D., the Danforth Chair in the Humanities at Saint Louis University, died Friday, June 20, 2025. She was 46. The Belgian-born philosopher examined why and how humans engage in pursuits that seem remote from the immediate concerns of survival and reproduction, such as theology, mathematics, and science.
- 'I am More Than Just a Refugee': A SLU Student Shares His StoryThe Saint Louis University-Jesuit Worldwide Learning (SLU-JWL) program offers remote bachelor's degrees to international students displaced by conflict, lack of opportunity, and poverty in places such as refugee camps in Kenya and Malawi. One student, Dictor Olame, reflected on his experience as a SLU student in the Kakuma refugee camp in North-Western Kenya.
- SLU Supports St. Louis by Hosting City's Tornado Relief CenterIn the weeks following a devastating tornado that tore through St. Louis on May 16, hundreds of households have turned to a centralized Disaster Assistance Center (DAC) at Chaifetz Arena for assistance.
- Persistence Pays Off for Fulbright Award RecipientAnuj Gandhi is a Fulbright Scholar. A year after being chosen as an alternate, Gandhi has been chosen for a Fulbright-Nehru Student Research Award. With the Award, the recent Saint Louis University graduate intends to "investigate how globalization-based acculturation influences Indian young adults' attitudes toward mental health and treatment options."